Anzeige
Mehr »
Freitag, 26.06.2026 - Börsentäglich über 12.000 News
Tagebau oder Tiefsee-Bergbau: Für welchen Fußabdruck entscheidet sich die Welt?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Pharmaceutical Technology

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
12:46Immunai and Boehringer partner to identify T-cell targets
12:46Tryngolza charts blockbuster course after FDA's hypertriglyceridemia approval
11:46Lilly-backed Absci banks $100m to progress endometriosis, hair loss therapy
11:46Ionis grants Recordati rights to zilganersen for Alexander disease
08:46BIO 2026: Former FDA staff question agency's "radical transparency" approach
DoMerck KGaA to buy Bio-Techne for $11.3bn in life science footprint expansion
DoMSD's Keytruda-Padcev combo secures EC approval for MIBC
DoRQ Bio secures $115m to develop influenza antibody programme
DoBIO 2026: How NIH cuts have threatened US competitiveness against China
MiNovartis targets undruggable cancers with $1.9bn Antares Therapeutics deal
MiOURA and Lilly join forces to harmonise drug-wearable obesity care
MiBoehringer and Combotope partner for cancer antibodies
MiHaisco and Nuvectis sign licensing deal for two drugs
DiBIO 2026: NVIDIA announces the BioNeMo toolkit for AI agents
DiFDA changes rare disease tune again as it clears path for Regenxbio's gene therapy
DiGenprex's Reqorsa combo secures Canadian patent for lung cancer
DiBIO 2026: Drug manufacturers band together to tackle employment challenges
DiLilly and BioArctic sign deal to develop neurodegenerative therapy
MoAbbVie deepens immunology legacy in $10.9bn Apogee buyout
MoHLTH Europe 2026: enriching the patient journey with health technologies
MoModerna's mRNA flu vaccine passes FDA AdCom, review underway
MoModerna's mRNA flu vaccine set for FDA review after positive AdCom
MoSun Pharma to acquire Innovcare Lifesciences for $28.7m
MoJapan approves Sanofi's Sarclisa combo for MM treatment
19.06.Biopharma industry confidence at highest in years despite geopolitical headwinds